Abstract
Mucositis is a side effect associated with the use of chemotherapy, and has a significant impact on the quality of life. Mucositis, by definition, refers to the inflammation of the mucosa and occurs throughout the alimentary tract from the mouth to anus. Nuclear Factor kappa B (NFκB) encompasses a family of transcription factors, which upregulate pro-inflammatory cytokines. These are recognized as key targets in developing therapeutic interventions for chemotherapy-induced mucositis, and cyclooxygenase (COX)-2 inhibition may also be beneficial in reducing the severity and duration. This review focuses on the pathobiology of chemotherapy-induced oral and gastrointestinal mucositis and recent research examining the role of agents with anti-inflammatory activity in treatment and prevention of the condition. We consider agents in clinical use as well as some others under current investigation including plant-derived and other natural medicines.
Keywords: Mucositis, chemotherapy, gastrointestinal, inflammation, anti-inflammatory, natural agents.
Current Pharmaceutical Design
Title:Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis
Volume: 24 Issue: 14
Author(s): Vaishnavi J. Mahendran, Andrea M. Stringer, Susan J. Semple, Yunmei Song and Sanjay Garg*
Affiliation:
- School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide,Australia
Keywords: Mucositis, chemotherapy, gastrointestinal, inflammation, anti-inflammatory, natural agents.
Abstract: Mucositis is a side effect associated with the use of chemotherapy, and has a significant impact on the quality of life. Mucositis, by definition, refers to the inflammation of the mucosa and occurs throughout the alimentary tract from the mouth to anus. Nuclear Factor kappa B (NFκB) encompasses a family of transcription factors, which upregulate pro-inflammatory cytokines. These are recognized as key targets in developing therapeutic interventions for chemotherapy-induced mucositis, and cyclooxygenase (COX)-2 inhibition may also be beneficial in reducing the severity and duration. This review focuses on the pathobiology of chemotherapy-induced oral and gastrointestinal mucositis and recent research examining the role of agents with anti-inflammatory activity in treatment and prevention of the condition. We consider agents in clinical use as well as some others under current investigation including plant-derived and other natural medicines.
Export Options
About this article
Cite this article as:
Mahendran J. Vaishnavi, Stringer M. Andrea, Semple J. Susan, Song Yunmei and Garg Sanjay*, Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis, Current Pharmaceutical Design 2018; 24 (14) . https://dx.doi.org/10.2174/1381612824666180409093918
DOI https://dx.doi.org/10.2174/1381612824666180409093918 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Prodrug Designing of NSAIDs
Mini-Reviews in Medicinal Chemistry Biological Properties of Citrus Flavonoids Pertaining to Cancer and Inflammation
Current Medicinal Chemistry Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Anti-Cancer
Current Bioactive Compounds Human Clinical Studies of Tea Polyphenols in Allergy or Life Style-related Diseases
Current Pharmaceutical Design A Review of the Possible Mechanisms of Action of Tocotrienol – A Potential Antiosteoporotic Agent
Current Drug Targets Targeting Extracellular Matrix Proteolysis for Hemorrhagic Complications of tPA Stroke Therapy
CNS & Neurological Disorders - Drug Targets GDF-15: A Multifunctional Modulator and Potential Therapeutic Target in Cancer
Current Pharmaceutical Design Editorial (Taking the Kidney Personally: The Quest for Novel Antigens of Idiopathic Membranous Nephropathy through Proteomic Approaches – Per Ardua Ad Astra?)
Current Pharmacogenomics and Personalized Medicine Vitamin A in Prevention of Bronchopulmonary Dysplasia
Current Pharmaceutical Design Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology Designing and Testing New Therapeutic Modalities for Treatment of Inflammatory Bowel Disease: Role of Experimental Animal Models
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy
Current Cancer Therapy Reviews Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology